Qing Zhu,1*† Jason S. McLellan,2† Nicole L. Kallewaard,1 Nancy D. Ulbrandt,1 Susan Palaszynski,1
Jing Zhang,1 Brian Moldt,1 Anis Khan,3 Catherine Svabek,1 Josephine M. McAuliffe,1
Daniel Wrapp,2 Nita K. Patel,1 Kimberly E. Cook,4 Bettina W. M. Richter,1 Patricia C. Ryan,5
Andy Q. Yuan,4 JoAnn A. Suzich1*
Most children with severe RSV infection were previously healthy term children. Palivizumab, the only approved agent for RSV prophylaxis, is limited to high-risk infants, and the cost associated with the requirement for dosing throughout the RSV season makes its use impractical for all infants. This paper describes the development of a monoclonal antibody as potential RSV prophylaxis for all infants with a single intramuscular dose. MEDI8897 has >50-fold higher activity than palivizumab. More than threefold increased half-life. Considering the half-life its use may be an option to protect all infants from RSV disease with once-per-RSV-season dosing.
Jing Zhang,1 Brian Moldt,1 Anis Khan,3 Catherine Svabek,1 Josephine M. McAuliffe,1
Daniel Wrapp,2 Nita K. Patel,1 Kimberly E. Cook,4 Bettina W. M. Richter,1 Patricia C. Ryan,5
Andy Q. Yuan,4 JoAnn A. Suzich1*
Most children with severe RSV infection were previously healthy term children. Palivizumab, the only approved agent for RSV prophylaxis, is limited to high-risk infants, and the cost associated with the requirement for dosing throughout the RSV season makes its use impractical for all infants. This paper describes the development of a monoclonal antibody as potential RSV prophylaxis for all infants with a single intramuscular dose. MEDI8897 has >50-fold higher activity than palivizumab. More than threefold increased half-life. Considering the half-life its use may be an option to protect all infants from RSV disease with once-per-RSV-season dosing.
| 2017_zhu_sci_transl_med_medi8897.pdf |
RSS Feed
